IPO and Fundraising - The company completed its Initial Public Offering (IPO) on July 15, 2024, raising gross proceeds of $230,000,000 from the sale of 23,000,000 Units at a price of $10.00 per Unit[22]. - An additional $6,000,000 was generated from the private sale of 6,000,000 Private Placement Warrants at a purchase price of $1.00 per warrant[23]. - The total amount of $230,000,000 from the IPO and Private Placement has been placed in a Trust Account[24]. - The Trust Account initially held $230,000,000 from the net proceeds of the IPO and Private Placement, which may be invested in U.S. government securities or held in cash[155]. - The company has $245,449,353 available for a Business Combination as of December 31, 2025, before redemptions and taxes[55]. - The company incurred transaction costs of $15,574,281 related to the Initial Public Offering, which included a cash underwriting fee of $4,000,000 and a deferred fee of $10,950,000[169]. Business Combination and Strategy - The company must complete its initial Business Combination by July 15, 2026, or face termination and distribution of Trust Account amounts[25]. - The Minovia Business Combination was mutually terminated on January 30, 2026, resulting in the release of all parties from liabilities related to the transaction[27]. - The management team is actively seeking alternative ways to consummate an initial Business Combination following the termination of the Minovia deal[29]. - The company is focused on identifying unique opportunities within the healthcare and life sciences sectors for its initial Business Combination[34]. - The company intends to complete its initial Business Combination with a target business that may be financially unstable or in early stages of development, which carries inherent risks[41]. - The company may structure its initial Business Combination to acquire less than 100% of the target business, provided it acquires at least 50% of the voting securities[47]. - The company intends to seek companies that align with its acquisition criteria, although it may consider targets that do not meet all specified criteria[38]. - The acquisition process includes a thorough due diligence review, which encompasses meetings with management, document reviews, and inspections of facilities[39]. Shareholder Rights and Redemption - Shareholders will have the opportunity to redeem their Public Shares at a per share price based on the amount in the Trust Account, expected to be approximately $10.67 per Public Share[45]. - A minimum of 8,625,001 Public Shares, or 37.5% of the 23,000,000 Public Shares sold in the Initial Public Offering, must be voted in favor of the initial Business Combination for it to be approved[76]. - Public Shareholders seeking redemption must deliver share certificates or use the DWAC System two business days prior to the scheduled vote on the initial Business Combination[80]. - If the initial Business Combination is not approved, Public Shareholders who elected to redeem will not receive their pro rata share of the Trust Account[88]. - The company will provide Public Shareholders with the opportunity to redeem their shares either through a general meeting or a tender offer, depending on the circumstances[73]. - The redemption price upon dissolution is expected to be approximately $10.67 per share as of December 31, 2025, but may be subject to creditor claims[94]. - The Trust Account may be reduced below $10.00 per Public Share due to claims, affecting the redemption amount for Public Shareholders[96]. - If cash consideration for redemptions exceeds available cash, the initial Business Combination will not be completed, and all submitted Public Shares will be returned[81]. Financial Performance and Risks - As of December 31, 2025, the company reported a net income of $8,309,154, primarily from interest earned on cash and marketable securities held in the Trust Account[167]. - The company incurred general and administrative costs of $1,611,081 for the year ended December 31, 2025[167]. - The company is subject to increased expenses due to being a public company, including legal and financial reporting costs[166]. - Management has determined that the company currently lacks the liquidity needed to sustain operations for at least one year, raising substantial doubt about its ability to continue as a going concern[178]. - The company may incur losses and reduce available funds if the initial Business Combination is not completed after costs associated with target evaluation[40]. - The company may face challenges in completing its initial Business Combination due to limited resources and significant competition for opportunities[116]. - The ongoing geopolitical conflicts, including the Russia-Ukraine war and tensions in the Middle East, could adversely affect the ability to find a target business for the initial Business Combination[126]. - The potential for significant volatility in commodity prices and market disruptions due to geopolitical tensions may impact the financial condition of potential target companies[127]. Corporate Governance and Compliance - The company is required to file annual, quarterly, and current reports with the SEC, ensuring transparency in financial reporting[103]. - The company is classified as an "emerging growth company," allowing it to take advantage of certain exemptions from reporting requirements[108]. - The company has established an Audit Committee consisting of three independent members, ensuring compliance with Nasdaq and SEC rules[216]. - The Audit Committee is tasked with pre-approving all audit and non-audit services provided by independent registered public accounting firms[218]. - The Compensation Committee oversees cybersecurity and information security policies, managing potential cybersecurity incidents[220]. - The company has two standing committees: the Audit Committee and the Compensation Committee, both composed of independent members[215]. - The company may amend certain agreements related to the Initial Public Offering without shareholder approval, which could impact shareholder rights[115]. - The company is subject to compliance obligations under the Sarbanes-Oxley Act, which may increase costs and complexity in completing the initial Business Combination[117]. Management and Board of Directors - The Chief Financial Officer has been with the company since inception and has extensive experience in managing finance and business operations[204]. - The board of directors consists of five members, with terms divided into three classes, each serving a three-year term[211]. - The company’s Board of Directors has the authority to appoint officers at its discretion, without specific terms of office[214]. - The Chairman of the Board has over 25 years of experience in global financial services and technology[202]. - The Chief Executive Officer has been with the company since inception and has a strong background in life sciences transactions[203]. - The board includes members with extensive experience in investment banking and financing pharmaceutical companies[206]. - The Compensation Committee, chaired by Mr. Ferguson, includes independent members and reviews annual and quarterly financial statements with management[219]. Legal and Regulatory Matters - There is currently no material litigation pending against the Company or its officers and directors[137]. - The company has no material legal proceedings involving any director or executive officer in the last ten years[210]. - The company may face regulatory review and approval requirements for its initial Business Combination, which could delay or prevent completion[120]. - The company may be subject to changing laws and regulations that increase costs and risks of non-compliance[120]. - The Company may be deemed a passive foreign investment company, leading to adverse U.S. federal income tax consequences for U.S. shareholders[129].
Launch One Acquisition Corp.(LPAA) - 2025 Q4 - Annual Report